Hansa Biopharma to Host Virtual Investor Event on Guillain-Barré Syndrome

Hansa Biopharma AB ( (SE:HNSA) ) has issued an update.

Hansa Biopharma announced a virtual investor event on Guillain-Barré syndrome (GBS) scheduled for June 16, 2025. The event will feature presentations from renowned medical professionals discussing the current treatment landscape and scientific advancements in GBS. Company executives will also outline Hansa’s activities and milestones in the autoimmune space. This event is part of a series aimed at the investor community, focusing on Hansa’s key areas of interest: Autoimmune, Gene Therapy, and Kidney Transplantation.

The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK175.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.

More about Hansa Biopharma AB

Hansa Biopharma AB is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative treatments for rare immunological conditions. The company leverages its proprietary IgG-cleaving enzyme technology platform to address unmet medical needs in autoimmune diseases, gene therapy, and transplantation. Its portfolio includes imlifidase, an IgG antibody-cleaving enzyme therapy, and HNSA-5487, a next-generation IgG cleaving molecule.

Average Trading Volume: 162,721

Current Market Cap: SEK1.64B

Learn more about HNSA stock on TipRanks’ Stock Analysis page.